Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) traded down 3.4% during trading on Friday . The stock traded as low as $7.43 and last traded at $7.45. 1,624,715 shares traded hands during trading, a decline of 46% from the average session volume of 2,983,978 shares. The stock had previously closed at $7.71.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the stock. Piper Sandler reduced their target price on shares of Hims & Hers Health from $11.00 to $10.00 in a research note on Tuesday, August 8th. Credit Suisse Group restated an “outperform” rating and set a $14.00 target price on shares of Hims & Hers Health in a research report on Tuesday, August 8th. TD Cowen initiated coverage on Hims & Hers Health in a report on Friday, July 28th. They issued an “outperform” rating and a $11.00 price target for the company. Finally, Truist Financial decreased their price objective on Hims & Hers Health from $12.00 to $10.00 and set a “hold” rating on the stock in a research note on Wednesday, August 9th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.36.
Hims & Hers Health Stock Down 4.0 %
Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its quarterly earnings data on Monday, November 6th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Hims & Hers Health had a negative return on equity of 11.22% and a negative net margin of 4.50%. The business had revenue of $226.70 million for the quarter, compared to analysts’ expectations of $220.08 million. During the same period in the previous year, the firm posted ($0.09) EPS. The firm’s revenue for the quarter was up 56.6% compared to the same quarter last year. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post -0.13 EPS for the current fiscal year.
Insider Transactions at Hims & Hers Health
In other news, insider Irene Becklund sold 10,596 shares of the company’s stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $6.31, for a total value of $66,860.76. Following the completion of the transaction, the insider now directly owns 5,494 shares in the company, valued at approximately $34,667.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Irene Becklund sold 10,596 shares of the business’s stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $6.31, for a total value of $66,860.76. Following the completion of the sale, the insider now directly owns 5,494 shares in the company, valued at approximately $34,667.14. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 6,698 shares of the business’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $6.92, for a total value of $46,350.16. Following the completion of the sale, the chief financial officer now directly owns 125,016 shares of the company’s stock, valued at approximately $865,110.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,798 shares of company stock valued at $523,299. Insiders own 31.63% of the company’s stock.
Institutional Trading of Hims & Hers Health
Institutional investors have recently made changes to their positions in the stock. Harbour Investments Inc. boosted its holdings in shares of Hims & Hers Health by 427.9% during the third quarter. Harbour Investments Inc. now owns 6,995 shares of the company’s stock worth $44,000 after purchasing an additional 5,670 shares during the period. Belpointe Asset Management LLC bought a new position in Hims & Hers Health during the 3rd quarter valued at approximately $76,000. Penserra Capital Management LLC lifted its holdings in Hims & Hers Health by 65.8% in the 3rd quarter. Penserra Capital Management LLC now owns 553,211 shares of the company’s stock worth $3,479,000 after buying an additional 219,616 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Hims & Hers Health by 37.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 71,023 shares of the company’s stock worth $447,000 after buying an additional 19,468 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Hims & Hers Health by 21.4% during the third quarter. Legal & General Group Plc now owns 145,028 shares of the company’s stock valued at $912,000 after buying an additional 25,545 shares during the period. Hedge funds and other institutional investors own 61.45% of the company’s stock.
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.
- Five stocks we like better than Hims & Hers Health
- There Are Different Types of Stock To Invest In
- 3 large caps with red hot RSIs with upside
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Johnson Controls International: Nothing but upside for investors
- 3 Monster Growth Stocks to Buy Now
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.